Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Moe Yamashita, Tetsuo Kobayashi, Satoshi Ito, Chihiro Kaneko, Akira Murasawa, Hajime Ishikawa & Koichi Tabeta. (2020) The periodontal inflamed surface area is associated with the clinical response to biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a retrospective study. Modern Rheumatology 30:6, pages 990-996.
Read now
Read now
Motohiko Aizu, Ichiro Mizushima, Satoshi Nakazaki, Akikatsu Nakashima, Takashi Kato, Takashi Murayama, Shinichi Kato, Yasuo Katsuki, Kunihiro Ogane, Hiroshi Fujii, Kazunori Yamada, Hideki Nomura, Akihiro Yachie, Masakazu Yamagishi & Mitsuhiro Kawano. (2018) Changes in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis. Modern Rheumatology 28:4, pages 592-598.
Read now
Read now
Satoshi Ito. (2018) Weekly subcutaneous injection of tocilizumab in patients with rheumatoid arthritis. Modern Rheumatology 28:1, pages 17-19.
Read now
Read now
Byeongzu Ghang, Ohchan Kwon, Seokchan Hong, Chang-Keun Lee, Bin Yoo & Yong-Gil Kim. (2017) Neutrophil-to-lymphocyte ratio is a reliable marker of treatment response in rheumatoid arthritis patients during tocilizumab therapy. Modern Rheumatology 27:3, pages 405-410.
Read now
Read now
Arata Nakajima, Yasuchika Aoki, Yoshifumi Shibata, Masato Sonobe, Fumiaki Terajima, Hiroshi Takahashi, Masahiko Saito, Shinji Taniguchi, Manabu Yamada & Koichi Nakagawa. (2014) Identification of clinical parameters associated with serum oxidative stress in patients with rheumatoid arthritis. Modern Rheumatology 24:6, pages 926-930.
Read now
Read now
Toshihisa Kojima, Yuichiro Yabe, Atsushi Kaneko, Yuji Hirano, Hisato Ishikawa, Masatoshi Hayashi, Hiroyuki Miyake, Hideki Takagi, Takefumi Kato, Kenya Terabe, Tsuyoshi Wanatabe, Hiroki Tsuchiya, Daihei Kida, Tomone Shioura, Koji Funahashi, Daizo Kato, Hiroyuki Matsubara, Nobunori Takahashi, Yosuke Hattori, Nobuyuki Asai & Naoki Ishiguro. (2013) Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Modern Rheumatology 23:5, pages 977-985.
Read now
Read now
Michio Fujiwara & Yasuhiko Kita. (2013) Reexamination of the assessment criteria for rheumatoid arthritis disease activity based on comparison of the Disease Activity Score 28 with other simpler assessment methods. Modern Rheumatology 23:2, pages 260-268.
Read now
Read now
Masahiko Mihara, Yoshiyuki Ohsugi & Tadamitsu Kishimoto. (2011) Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis. Open Access Rheumatology: Research and Reviews 3, pages 19-29.
Read now
Read now
Isamu Yokoe, Shinya Nishio, Hiroshi Sato & Hitomi Kobayashi. (2011) Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks. Modern Rheumatology 21:6, pages 710-714.
Read now
Read now
Shin-ya Kawashiri, Atsushi Kawakami, Naoki Iwamoto, Keita Fujikawa, Toshiyuki Aramaki, Mami Tamai, Satoshi Yamasaki, Hideki Nakamura, Tomoki Origuchi, Yukitaka Ueki, Kiyoshi Migita, Akinari Mizokami, Kiyoshi Aoyagi & Katsumi Eguchi. (2011) In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Modern Rheumatology 21:4, pages 370-374.
Read now
Read now
Shin-ya Kawashiri, Atsushi Kawakami, Naoki Iwamoto, Keita Fujikawa, Toshiyuki Aramaki, Mami Tamai, Satoshi Yamasaki, Hideki Nakamura, Yukitaka Ueki, Kiyoshi Migita, Akinari Mizokami, Tomoki Origuchi, Kiyoshi Aoyagi & Katsumi Eguchi. (2011) Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index. Modern Rheumatology 21:4, pages 365-369.
Read now
Read now
Charles J Malemud. (2009) Recent advances in neutralizing the IL-6 pathway in arthritis. Open Access Rheumatology: Research and Reviews 1, pages 133-150.
Read now
Read now
Articles from other publishers (14)
Tetsuo Kobayashi & Peter Mark Bartold. (2023) Periodontitis and periodontopathic bacteria as risk factors for rheumatoid arthritis: A review of the last 10 years. Japanese Dental Science Review 59, pages 263-272.
Crossref
Crossref
Tetsuo Kobayashi, Satoshi Ito, Akira Murasawa, Hajime Ishikawa & Koichi Tabeta. (2023)
The serum immunoglobulin G titres against
Porphyromonas gingivalis
as a predictor of clinical response to 1-year treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: A retrospective cohort study
. Modern Rheumatology 33:5, pages 918-927.
Crossref
Crossref
Tetsuo Kobayashi, Satoshi Ito, Akira Murasawa, Hajime Ishikawa & Koichi Tabeta. (2023) Periodontitis severity affects the clinical response to biological disease-modifying antirheumatic drugs in rheumatoid arthritis: A 1-year follow-up study. Modern Rheumatology 33:1, pages 81-87.
Crossref
Crossref
Jina Yeo, Han Joo Baek, Yeong Wook Song & Eun Young Lee. (2022) Evaluation of Serum Matrix Metalloproteinase-3 as an Objective Indicator for the Disease Activity in Rheumatoid Arthritis Patients Treated With Methotrexate Versus Tocilizumab: 24-week Results From a Prospective Randomized Controlled Study. Journal of Rheumatic Diseases 29:2, pages 89-97.
Crossref
Crossref
Akio Kawabe, Kazuhisa Nakano, Satoshi Kubo, Takeshi Asakawa & Yoshiya Tanaka. (2020) Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry. Arthritis Research & Therapy 22:1.
Crossref
Crossref
Aaron Lerner, Sandra Neidhöfer, Sandra Reuter & Torsten Matthias. (2018) MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 32:4, pages 550-562.
Crossref
Crossref
César E. Fors Nieves, Bruce N. Cronstein & Amit Saxena. 2017. Kelley and Firestein's Textbook of Rheumatology. Kelley and Firestein's Textbook of Rheumatology
846
857.e4
.
Jian-Da Ma, Xiu-Ning Wei, Dong-Hui Zheng, Ying-Qian Mo, Le-Feng Chen, Xiang Zhang, Jin-Hua Li & Lie Dai. (2015) Continuously elevated serum matrix metalloproteinase-3 for 3?~?6?months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study. Arthritis Research & Therapy 17:1.
Crossref
Crossref
Koichi Okamura, Yukio Yonemoto, Chisa Okura, Tetsuya Higuchi, Yoshito Tsushima & Kenji Takagishi. (2014) Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT. BMC Musculoskeletal Disorders 15:1.
Crossref
Crossref
Sohita Dhillon. (2013) Intravenous Tocilizumab: A Review of Its Use in Adults with Rheumatoid Arthritis. BioDrugs 28:1, pages 75-106.
Crossref
Crossref
Amit Saxena & Bruce N. Cronstein. 2013. Kelley's Textbook of Rheumatology. Kelley's Textbook of Rheumatology
818
829.e4
.
Jeroen DeGroot, Anne-Marie Zuurmond & Paul-Peter Tak. 2013. Kelley's Textbook of Rheumatology. Kelley's Textbook of Rheumatology
476
492.e6
.
Stefan Bittner, Nicole Bobak, Martin Feuchtenberger, Alexander M Herrmann, Kerstin Göbel, Raimund W Kinne, Anker J Hansen, Thomas Budde, Christoph Kleinschnitz, Oliver Frey, Hans-Peter Tony, Heinz Wiendl & Sven G Meuth. (2011) Expression of K2P5.1 potassium channels on CD4+T lymphocytes correlates with disease activity in rheumatoid arthritis patients. Arthritis Research & Therapy 13:1.
Crossref
Crossref
Keiko FUNAHASHI, Tetsuya TAKAMATSU & Tsukasa MATSUBARA. (2011) Progress in the Treatment of Rheumatoid Arthritis and Decreasing Number of Patients Participating in Clinical Trials. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 42:6, pages 401-407.
Crossref
Crossref